Exodus Point Capital Management, LP Actinium Pharmaceuticals, Inc. Transaction History

Exodus Point Capital Management, LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 10, 2023	SELL	$7.15 - $9.39 $16,752 - $22,000	-2,343 Reduced 3.89%	57,934 $430,000
Q1 2023 May 11, 2023	BUY	$8.51 - $14.26 $118,544 - $198,641	13,930 Added 30.06%	60,277 $570,000
Q4 2022 Feb 13, 2023	BUY	$9.71 - $12.51 $450,029 - $579,800	46,347 New	46,347 $494,000
Q4 2021 Feb 11, 2022	SELL	$6.01 - $8.8 $106,978 - $156,640	-17,800 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$5.76 - $9.67 $102,528 - $172,126	17,800 New	17,800 $158,000

Q1 2021 May 17, 2021	SELL	$7.62 - $9.79 $90,678 - $116,500	-11,900 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$7.8 - $12.64 $92,820 - $150,416	11,900 New	11,900 $93,000

6.65M

369K

148K

Ticker ATNM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,184,700
Market Cap $186M
Description
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly re...

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Exodus Point Capital Management, LP with notifications on news.